Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Desirèe SperanzaDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0009-0005-5108-1052
Fausto OmeroDepartment of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, 98125 Messina, Italy.ORCID 0009-0001-4202-3855
Vincenzo CianciDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Legal Medicine, University of Messina, 98125 Messina, Italy.ORCID 0009-0003-1274-3514
Mariapia MarafiotiDepartment of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, 98125 Messina, Italy.
Carla InfurnaDepartment of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, 98125 Messina, Italy.
Patrizia CarroccioDepartment of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, 98125 Messina, Italy.ORCID 0009-0008-0529-0816
Edoardo SpinaDepartment of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.ORCID 0000-0002-2509-7449
Maria Antonietta BarbieriDepartment of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.ORCID 0000-0002-2019-4696
Emanuela EspositoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0002-2663-6387
Nicola SilvestrisMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.ORCID 0000-0001-7814-7318
Mariacarmela SantarpiaMedical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance. · full record | OpenQuestion